fluconazole has been researched along with antimicrobial peptide ib-367 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arzeni, D; Barchiesi, F; Cirioni, O; Della Vittoria, A; Giacometti, A; Kamysz, W; Licci, A; Marigliano, A; Nadolski, P; Scalise, G; Silvestri, C; Ĺukasiak, J | 1 |
| Arzeni, D; Barchiesi, F; Castelli, P; Cirioni, O; Conte, I; Giacometti, A; Kamysz, E; Kamysz, W; Morciano, A; Offidani, AM; Orsetti, E; Scalise, A; Silvestri, C; Simonetti, O; Staffolani, S | 1 |
2 other study(ies) available for fluconazole and antimicrobial peptide ib-367
| Article | Year |
|---|---|
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
Topics: Amphotericin B; Antifungal Agents; Antimicrobial Cationic Peptides; Candida; Candidiasis; Drug Resistance, Fungal; Drug Synergism; Drug Therapy, Combination; Fluconazole; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Peptides | 2007 |
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes.
Topics: Antifungal Agents; Antimicrobial Cationic Peptides; Arthrodermataceae; Colony Count, Microbial; Dermatomycoses; Drug Synergism; Fluconazole; Humans; Hyphae; Itraconazole; Microbial Sensitivity Tests; Microbial Viability; Naphthalenes; Terbinafine | 2014 |